PE20231318A1 - Compuestos heteroarilicos sustituidos utiles como inhibidores de tlr9 - Google Patents

Compuestos heteroarilicos sustituidos utiles como inhibidores de tlr9

Info

Publication number
PE20231318A1
PE20231318A1 PE2023000276A PE2023000276A PE20231318A1 PE 20231318 A1 PE20231318 A1 PE 20231318A1 PE 2023000276 A PE2023000276 A PE 2023000276A PE 2023000276 A PE2023000276 A PE 2023000276A PE 20231318 A1 PE20231318 A1 PE 20231318A1
Authority
PE
Peru
Prior art keywords
phenyl
hydrogen
substituted heteroaryl
heteroaryl compounds
compounds useful
Prior art date
Application number
PE2023000276A
Other languages
English (en)
Spanish (es)
Inventor
Chunjian Liu
Alicia Regueiro-Ren
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20231318A1 publication Critical patent/PE20231318A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2023000276A 2020-08-19 2021-08-18 Compuestos heteroarilicos sustituidos utiles como inhibidores de tlr9 PE20231318A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063067389P 2020-08-19 2020-08-19
PCT/US2021/046475 WO2022040293A1 (en) 2020-08-19 2021-08-18 Substituted heteroaryl compounds useful as inhibitors of tlr9

Publications (1)

Publication Number Publication Date
PE20231318A1 true PE20231318A1 (es) 2023-08-24

Family

ID=77726550

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000276A PE20231318A1 (es) 2020-08-19 2021-08-18 Compuestos heteroarilicos sustituidos utiles como inhibidores de tlr9

Country Status (17)

Country Link
US (1) US20230322770A1 (enExample)
EP (1) EP4200015B1 (enExample)
JP (1) JP7868034B2 (enExample)
KR (1) KR20230052930A (enExample)
CN (1) CN115956077A (enExample)
AR (1) AR123284A1 (enExample)
AU (1) AU2021328362A1 (enExample)
BR (1) BR112023002662A2 (enExample)
CA (1) CA3189816A1 (enExample)
CL (1) CL2023000428A1 (enExample)
CO (1) CO2023001670A2 (enExample)
ES (1) ES3070309T3 (enExample)
IL (1) IL300696A (enExample)
MX (1) MX2023001883A (enExample)
PE (1) PE20231318A1 (enExample)
TW (1) TW202227431A (enExample)
WO (1) WO2022040293A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4267560A1 (en) * 2020-12-22 2023-11-01 Gilead Sciences, Inc. 6-substituted indole compounds
EP4267559A1 (en) * 2020-12-22 2023-11-01 Gilead Sciences, Inc. Substituted indole compounds
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
TW202440078A (zh) 2021-09-10 2024-10-16 美商基利科學股份有限公司 噻吩并吡咯化合物
MX2024009441A (es) * 2022-02-18 2024-08-14 Bristol Myers Squibb Co Compuestos de imidazopiridinilo sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9).
WO2024102886A1 (en) * 2022-11-10 2024-05-16 Bristol-Myers Squibb Company Substituted benzimidazole compounds useful as inhibitors of tlr9
CN120152957A (zh) * 2022-11-10 2025-06-13 百时美施贵宝公司 用作tlr9抑制剂的经取代的喹诺酮

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158049A1 (en) * 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 7-azaindole inhibitors of crac
US9643967B2 (en) 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
AR103232A1 (es) * 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
MX2020006168A (es) * 2017-12-18 2020-08-13 Bristol Myers Squibb Co Compuestos de 4-azaindol.
EP3728253B1 (en) * 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
KR102730859B1 (ko) * 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물

Also Published As

Publication number Publication date
IL300696A (en) 2023-04-01
BR112023002662A2 (pt) 2023-03-14
US20230322770A1 (en) 2023-10-12
MX2023001883A (es) 2023-03-10
CL2023000428A1 (es) 2023-07-28
AU2021328362A1 (en) 2023-03-23
EP4200015C0 (en) 2026-04-29
WO2022040293A1 (en) 2022-02-24
TW202227431A (zh) 2022-07-16
CN115956077A (zh) 2023-04-11
EP4200015A1 (en) 2023-06-28
CA3189816A1 (en) 2022-02-24
CO2023001670A2 (es) 2023-02-27
AR123284A1 (es) 2022-11-16
ES3070309T3 (es) 2026-06-15
JP2023539136A (ja) 2023-09-13
EP4200015B1 (en) 2026-04-29
KR20230052930A (ko) 2023-04-20
JP7868034B2 (ja) 2026-06-01

Similar Documents

Publication Publication Date Title
PE20210040A1 (es) Moduladores de la via de estres integrada
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20190732A1 (es) Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
PE20090546A1 (es) Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5
PE20040189A1 (es) Pirimidina y piridina biciclicos como inhibidores de p38 quinasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
ES2564010T3 (es) Composición farmacéutica para tratar o prevenir el glaucoma
PE20140390A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
PE20091039A1 (es) IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10
PE20090773A1 (es) Derivados de morfolina pirimidina
PE20141110A1 (es) Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos
PE20120659A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20141120A1 (es) Compuestos heterociclicos
AR078228A1 (es) Inhibidores de cyp17
AR076264A1 (es) Triazolopiridinas sustituidas y analogos de estas
PE20110328A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de la orexina
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
JP2020504747A5 (enExample)
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20161443A1 (es) Compuestos
PE20090984A1 (es) Inhibidores de peptido desformilasa
AR080688A1 (es) Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina